Paul Stoffels, Galapagos CEO (Michael Kovac/Getty Images)
June 21, 2022 04:01 PM EDTUpdated June 22, 10:54 AM
Deals

Gala­pa­gos CEO Paul Stof­fels bets €225M on a new CAR-T strat­e­gy for the long suf­fer­ing biotech

John Carroll

Editor & Founder

Tyler Patchen

News Reporter

The deeply trou­bled Eu­ro­pean biotech Gala­pa­gos and its new CEO Paul Stof­fels are go­ing the CAR-T route, and they have a new, €225 mil­lion buy­out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times